HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
批准号:
9335956
负责人:
Janice J Endsley
金额:
$70.56万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2019-06-30
关键词:
AddressAggressive courseAlveolar MacrophagesAnimal ModelAnti-Bacterial AgentsAnti-Retroviral AgentsAntibacterial ResponseAwardBiological AssayBiological AvailabilityCASP1 geneCD4 Positive T LymphocytesCause of DeathCell DeathCellsClinicalComplementControlled StudyDefectDevelopmentDiseaseDrug InteractionsEnvironmentFunctional disorderGranulomatousGrowthHIVHIV InfectionsHIV-1HumanImmuneImmune System DiseasesImmune System and Related DisordersImmune responseImmunityImmunologicsIn VitroIndividualInfectionInflammasomeInflammationInflammatoryInflammatory ResponseInnate Immune ResponseInterleukin-17InterventionKnowledgeLungMalabsorption SyndromesMeasuresMediatingModelingMolecularMusMycobacterium tuberculosisNecrosisNeutrophil InfiltrationOutcomePathogenicityPathologicPathologyPathway interactionsPersonsPlayPopulationPublic HealthPulmonary PathologyResearchRiskRoleSignal TransductionSiteSplenocyteT-LymphocyteTNF geneTestingTissuesTuberculosisWorkanimal imagingchemokinechemotherapyco-infectioncytokineexperimental studygain of functionhuman diseasehuman subjecthumanized mouseimmunopathologyimprovedin vivoinflammatory milieuinsightmacrophagememory CD4 T lymphocytemicrobialmonocytemouse modelmycobacterialneutrophilnovelnovel therapeuticsresponserestorationsynergismtargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Tuberculosis (TB) is the leading cause of death in people living with HIV infection. An increased risk of TB
precedes CD4+ T cell depletion and can continue following restoration of T cells by anti-retroviral (ARV)
therapy. Treatment of co-infected persons is challenging due to the aggressive course of both individual
diseases; a clinical problem that is further complicated by drug interaction and malabsorption issues when
combining ARVs and TB chemotherapy. Addressing these clinical challenges requires a much greater
understanding of co-infection pathophysiology. A critical knowledge gap has developed in the field due to the
limited availability of animal models that support HIV replication. To address this gap we developed a novel
model of TB/HIV in the BLT humanized mouse (HuMouse) that reproduces important pathological and
immunological features of human disease. By using our unique animal model, we are now able to study the
microbial synergy of HIV-1 and Mycobacterium tuberculosis (Mtb) infection in the lung. As a result, we have
identified candidate molecular mechanisms for co-infection synergy in lung macrophages (M) that promote a
pro-inflammatory environment and increase mycobacterial proliferation. The objective of this R01 application
is to use the new HuMouse model of TB/HIV co-infection to further elucidate the mechanisms whereby HIV
infection disrupts the innate immune response of pulmonary M to Mtb. Our hypothesis is that
inflammasome-dependent activation of IL-1 in pulmonary M due to HIV-1 infection drives a
hyperinflammatory response to Mtb, which in turn produces neutrophil-mediated lung damage and
increased tissue necrosis. We have two aims to test the following individual hypotheses that 1) HIV and Mtb
co-infection drive a pro-inflammatory lung environment via inflammasome-dependent activation of IL-1 in host
M, and 2) development of a Th17 cell bias due to the pro-inflammatory environment of co-infection leads to
IL-17-dependent neutrophil recruitment and damage in the lungs. These aims will be accomplished by using in
vivo studies with Mtb/HIV co-infected humanized mice and in vitro mechanistic studies with isolated lung M.
The expected outcome of our work is a significant advance in our understanding of how HIV manipulates the
host inflammatory response to Mtb to promote aggressive disease. The positive impact of these results will be
identification of new targets to intervene clinically to restore normal host immunity and reduce disease in
millions of HIV-infected people.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
-
批准号:10418739
-
项目类别:
-
资助金额:$95.94万
-
财政年份:2021
-
负责人:Janice J Endsley
-
依托单位:
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
-
批准号:10640122
-
项目类别:
-
资助金额:$95.94万
-
财政年份:2021
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:9538016
-
项目类别:
-
资助金额:$74.83万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:10390479
-
项目类别:
-
资助金额:$77.57万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:10092516
-
项目类别:
-
资助金额:$77.57万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
-
批准号:10159205
-
项目类别:
-
资助金额:$77.57万
-
财政年份:2018
-
负责人:Janice J Endsley
-
依托单位:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
-
批准号:9204582
-
项目类别:
-
资助金额:$71.94万
-
财政年份:2016
-
负责人:Janice J Endsley
-
依托单位:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
-
批准号:9129330
-
项目类别:
-
资助金额:$63.76万
-
财政年份:2015
-
负责人:Janice J Endsley
-
依托单位:
Self-assembling Peptide Nanomaterials for Eliciting Mucosal CD8+ T cell Immunity
-
批准号:9036015
-
项目类别:
-
资助金额:$22.76万
-
财政年份:2015
-
负责人:Janice J Endsley
-
依托单位:
A Humanized Mouse Model to Study HIV/Mtb Co-infection
-
批准号:7930463
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Janice J Endsley
-
依托单位:
A Humanized Mouse Model to Study HIV/Mtb Co-infection
-
批准号:8046356
-
项目类别:
-
资助金额:$22.72万
-
财政年份:2010
-
负责人:Janice J Endsley
-
依托单位: